SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

ICCC

ImmuCell Corporation
BULLISH
Impact 5/10
Horizonweeks Processed9d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Revenue growth accelerated to 46% with improving margins and a return to profitability. The termination of the ATM and new credit line suggest management sees no near-term capital need. Monitor Q4 peak-season sales and the signing of the new credit facility.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$10.75
T+0 close · Nov 12, 2026 · via day close
Latest settled
+1.58%
T+5 · $10.92
Vs SPY
+10.14%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 13 $10.75entry
  2. T+1 · 6d ago +6.23%α +8.14% · $11.42
  3. T+5 · 2d ago +1.58%α +10.14% · $10.92
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmuCell reported Q3 2026 net income of $953,000 ($0.10/diluted share) versus a net loss of $140,000 in Q3 2025, with product sales up 46% to $8.0 million. The company also terminated its At-The-Market offering and is negotiating a new $3 million line of credit.

Key Financial Metrics

EPS
$0.10
Revenue
$8.0M
+46.0% YoY
Gross Margin
44.2%

Key Facts

  • Q3 2026 product sales $8.0M, up 46% from $5.5M in Q3 2025
  • Net income $953,000 ($0.10/diluted) vs net loss $140,000 in Q3 2025
  • Gross margin improved to 44.2% from 42.9%
  • Adjusted EBITDA $1.9M vs $0.8M in Q3 2025
  • Cash and equivalents $7.9M vs $3.8M at Dec 31, 2025
  • Terminated At-The-Market offering
  • Negotiating new $3M line of credit expected to sign in Q4 2026

Financial Impact

Revenue up 46% to $8.0M; net income swing of +$1.1M from loss to profit; cash increased $4.1M

revenuenet incomegross margincash

Risk Factors

  • Revenue growth partly aided by easy comp from prior-year distributor destocking
  • Product development expenses shifted to COGS may pressure gross margins if not sustained
  • Small market cap ($93M) amplifies volatility from any single-quarter variance

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402176

Track record

8 reports on ICCC

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 19, 20262d ago 8-K/A Bullish 5/10 Entry $11.27 Now $10.92 −3.13% settles Nov 30
  2. Nov 12, 20269d ago Press Release Bullish 5/10 Viewing Entry $10.75 to $10.92 Now $10.92 +1.58% ▲ +1.58% +10.14% vs SPY
  3. Oct 13, 20265w ago 8-K Bullish 6/10 Entry $10.79 to $10.45 Now $10.92 +1.20% ▼ −3.15% −2.00% vs SPY
  4. May 8, 202628w ago 8-K Bullish 4/10 Entry $8.45 to $9.91 Now $10.92 +29.23% ▲ +17.28% +17.36% vs SPY
  5. Apr 8, 202632w ago 8-K Bullish 7/10 No price data
  6. Apr 8, 202632w ago Press Release Mixed 6/10 Entry $7.19 to $7.54 Now $10.92 +51.88% ▲ +4.87% +1.68% vs SPY
  7. Mar 4, 202637w ago 8-K Mixed 6/10 Entry $6.35 to $6.63 Now $10.92 +71.97% ▲ +4.41% +6.65% vs SPY
  8. Mar 4, 202637w ago Press Release Mixed 6/10 Entry $6.35 to $6.63 Now $10.92 +71.97% ▲ +4.41% +6.65% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens Mon (26h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026